Potassium Chloride
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
- Potassium Chloride
- Pharmacist Assessment Report
- Potassium Chloride: Renal tubular acidosis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Other Predicted Indications
- Conclusion and Next Steps
- Disclaimer
Potassium Chloride: Renal tubular acidosis
One-Sentence Summary
Potassium chloride is an electrolyte replacement originally used to treat potassium deficiency. The TxGNN model predicts it may be useful for renal tubular acidosis (RTA), but there are no registered clinical trials and the 18 publications retrieved are mostly case reports and reviews, so this is a supportive-care signal rather than evidence of disease-modifying benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Renal tubular acidosis |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L4 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, potassium chloride is a potassium salt used to replace potassium. Its efficacy in correcting potassium deficiency is well established, and it may be applicable to RTA only as supportive therapy.
Distal RTA commonly causes urinary potassium wasting and hypokalaemia. Potassium repletion, including KCl, therefore corrects the electrolyte disturbance. The case reports describe this, for example hypokalaemic paralysis in pregnancy and Sjögren-associated RTA treated with intravenous KCl.
However, KCl does not correct the underlying acidification defect. Alkali therapy (such as potassium citrate or bicarbonate) is the standard treatment. The high TxGNN score most likely reflects the potassium-deficiency link, not a disease-modifying effect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The literature is dominated by case reports, small cohorts and narrative reviews. No RCTs were identified. Selected relevant publications:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38445406 | 2023 | Cohort | La Tunisie Medicale | Genotype-phenotype study of distal RTA, which features hypokalaemia, hypercalciuria and nephrocalcinosis |
| 6277192 | 1982 | Review | Am J Med | Review of distal nephron function disorders |
| 786013 | 1976 | Review | Am J Med Sci | Causes, consequences and correction of hypokalaemia |
| 40288831 | 2025 | Case report/Review | Nefrologia | Primary RTA in pregnancy and perinatal prognosis |
| 34748193 | 2022 | Case report | J Nephrol | Distal RTA with hypokalaemic periodic paralysis during pregnancy |
| 37727491 | 2023 | Case report | World J Clin Cases | Incomplete distal RTA uncovered during pregnancy |
| 34595212 | 2021 | Case report | Case Rep Nephrol Dial | Type I RTA with severe hypokalaemia (K 1.6 mEq/L) in Sjögren’s/SLE, treated with intravenous KCl |
| 28509102 | 2015 | Case report | CEN Case Reports | Paediatric Sjögren syndrome with distal RTA and autoimmune hypothyroidism |
| 16076719 | 2005 | Case report | Acta Oto-Laryngologica | Distal RTA with large vestibular aqueduct and hearing loss |
| 10213645 | 1999 | Cohort | Am J Kidney Dis | Metabolic acidosis in advanced renal failure, diabetic vs non-diabetic patients |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13357B | Span-K | Tablet 600 mg (sustained release) | Not available in the data compiled for this report |
The only registered form is oral. No other routes (such as intravenous) appear in the data compiled for this report.
Safety Considerations
Contraindications and conditions of concern (associations, not label text): Potassium chloride is associated with caution or contraindication in the following groups:
- Renal: kidney disease, anuria
- Cardiovascular: congestive heart failure, heart disease, cardiovascular disease, coronary artery disease, hypertension
- Gastrointestinal: gastric ulcer, peptic ulcer disease, pancreatitis
- Hepatic and biliary: liver disease, gallbladder disease
- Other: hypercalcaemia, sarcoidosis, sickle cell anaemia, epilepsy, COPD, benign prostatic hyperplasia
Gastrointestinal injury: The literature retrieved for the gastric-disease predictions consistently reports upper GI mucosal injury and ulceration with solid KCl formulations, particularly wax-matrix preparations. This is relevant because the only Australian product is a sustained-release tablet.
Drug interactions: The interaction check returned 100 interactions. The main Major-level interactions include:
- Potassium-sparing diuretics: amiloride
- ACE inhibitors and ARBs: benazepril, olmesartan, valsartan, azilsartan medoxomil
- Anticholinergics and antihistamines (these slow GI transit and increase mucosal exposure): atropine, hyoscyamine, homatropine, glycopyrronium, benzatropine, biperiden, chlorpheniramine, brompheniramine, acrivastine, phenyltoloxamine
- Tricyclic antidepressants: amitriptyline
Moderate interactions include NSAIDs (ibuprofen, ketorolac) and aliskiren. Please also refer to the TGA-approved Product Information (PI) for full safety information, as label warnings were not available in the data compiled for this report.
Other Predicted Indications
The other predictions have no clinical trials and no supportive evidence, and all are rated L5 / Hold:
- These signals represent adverse-effect associations, not repurposing opportunities, and treatment would be potentially harmful.
Conclusion and Next Steps
Decision: Hold
Rationale: The RTA prediction rests on case reports and reviews that describe potassium repletion as supportive care. KCl does not treat the underlying acidification defect, for which alkali therapy is standard. There are no registered trials, and the other predicted indications have no supporting evidence or point to potential harm.
To proceed, the following is needed:
- Clarification of whether the intent is potassium correction in RTA (already within the existing potassium-deficiency use) or a new disease-modifying claim
- Comparative evidence against alkali therapy (potassium citrate or bicarbonate)
- The Australian PI warnings and contraindications, and the approved indication text for Span-K
- Mechanism of action data
- Assessment of GI safety of sustained-release tablets in this population, and of renal function and hyperkalaemia monitoring needs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.